TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00720759
Drug: Placebo + distributed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
Study: NCT02146664
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Study: NCT02146664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Study: NCT03944031
Drug: LY3372689
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00437762
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection
Study: NCT00688064
Drug: Vehicle Gel associated with Doxycycline Hyclate
Normalized name: doxycycline hyclate Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Study: NCT01706328
Drug: FF/VI 100/25 Inhalation Powder NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
Study: NCT01706328
Drug: Placebo Inhalation Powder NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
Study: NCT01706328
Drug: Placebo Inhalation Powder ACCUHALER/DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
Study: NCT04468711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus topical 1% hydrocortisone cream twice daily
Study: NCT00787761
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume).
Study: NCT01138072
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg once daily
Study: NCT00787761
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push.
Study: NCT02162316
Drug: Motilitone®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02162316
Drug: A-Cilin®, Clari® and Pantoline®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04326829
Drug: QL1604
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL1604, IV infusion
Study: NCT01138072
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg Simvastatin single dose
Study: NCT01138072
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg rosuvastatin single dose
Study: NCT03325114
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
Study: NCT03797664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate Buffer Diluent oral solution
Study: NCT01346085
Drug: CNI free immunosuppression
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
Study: NCT00118105
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre \& Post Operative: 1,700 mg/m\^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
Study: NCT02767232
Drug: Standard Anticoagulation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation determined by physician for a period of 3-6 months
Study: NCT00055978
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally. 400mg twice daily for 6 months.
Study: NCT00417690
Drug: PASER placebo granules
Normalized name: Paser D/R Granule Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
Study: NCT00331890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As active drug
Study: NCT04484337
Drug: Topical non-steroidal anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug will be available for topical application
Study: NCT04484337
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid will be available for topical application
Study: NCT04484337
Drug: Placebo creams/gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo creams/gels will be available for topical application
Study: NCT00622609
Drug: GSK249320A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
Study: NCT00622609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride intravenous infusion will be given as matching placebo.
Study: NCT00337571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily, 8 weeks
Study: NCT03856970
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 μg tablets for oral administration
Study: NCT02386033
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study: NCT03746431
Drug: [225Ac]-FPI-1434 Injection multi-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
Study: NCT03746431
Drug: [225Ac]-FPI-1434 Injection single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
Study: NCT02296073
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
Study: NCT00092807
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03023787
Drug: Hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Study: NCT03023787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
Study: NCT03353220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is made to mimic Belviq, but does not contain any active drug
Study: NCT02279953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04670679
Drug: ERAS-601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01531205
Drug: Androgen Ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
Study: NCT01531205
Drug: Salvage Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
Study: NCT00959751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg capsules with no active ingredient designed to match the NXN-188 capsules
Study: NCT03218501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is to be administered orally once daily for 2 weeks
Study: NCT00498550
Drug: Treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remain on pre-study antipsychotic treatment
Study: NCT03861039
Drug: Oral antihyperglycemic medication (OAM)
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihyperglycemic medication (OAM): Sulfonylurea, biguanide, alpha-glucosidase inhibitor, thiazolidinedione, glinide, or sodium-glucose cotransporter type 2 inhibitor.
Study: NCT01089647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
Study: NCT02060006
Drug: Meloxicam 7.5mg daily for 8 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5mg daily for 8 weeks
Study: NCT01566370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01168141
Drug: ZD4054
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg ZD4054 daily in tablet form
Study: NCT00332280
Drug: AMT2003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02388919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic dosage, take once when limosis in the morning.
Study: NCT02212067
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
Study: NCT03392298
Drug: Colla corii asini
Normalized name: CORID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g Colla corii asini granule, once daily for 4 weeks
Study: NCT00586625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop, both eyes, twice a day
Study: NCT00551447
Drug: MK0733, simvastatin / Duration of Treatment: 27 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00551447
Drug: Comparator: simvastatin / Duration of Treatment: 27 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02021773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study: NCT00870727
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be identical in size and appearance to study drug.
Study: NCT00720278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg Placebo daily
Study: NCT01712516
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
Study: NCT01712516
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT01712516
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT01712516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
Study: NCT01675609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye daily for up to 35 days
Study: NCT00737048
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen two oral capsules will be administered once as 650 mg.
Study: NCT00737048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
Study: NCT00737048
Drug: Tramadol plus Acetaminophen
Normalized name: acetaminophen / tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
Study: NCT00090532
Drug: AG-013,958
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04576000
Drug: Janus Kinase Inhibitor
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)
Study: NCT01196507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
Study: NCT01870284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00219609
Drug: UK-390,957
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01345019
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Study: NCT01345019
Drug: Placebo to zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion over 15 minutes once every 4 weeks
Study: NCT02864758
Drug: Vitamin K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, dose is based on International Normalized Ratio
Study: NCT01375322
Drug: Valsartan+Hydrochlorothiazide
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
Study: NCT00136201
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00950807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive/ excipients only
Study: NCT00950807
Drug: GSK573179
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573179 investigational drug
Study: NCT04276883
Drug: Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Film for BXCL501
Study: NCT01434121
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
Study: NCT01434121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741871
Drug: SB1518
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
Study: NCT04534283
Drug: LY3214996
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
Study: NCT01041781
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01243996
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
Study: NCT01648764
Drug: LY2334737
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01464138
Drug: Fosmidomycin and Clindamycin co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
Study: NCT00980876
Drug: Ciprofloxacin HCl and Hydrocortisone
Normalized name: ciprofloxacin / hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin Hydrochloride and Hydrocortisone
Study: NCT03979313
Drug: MEDI8897
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RSV monoclonal antibody with an extended half-life
Study: NCT03979313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% (w/v) saline
Study: NCT02056678
Drug: acetaminophen, IV preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00330070
Drug: IPL512,602 20 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00330070
Drug: IPL512,602 Matching Placebo once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999868
Drug: UST Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
Study: NCT01999868
Drug: ABA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
Study: NCT00574639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
Study: NCT02560467
Drug: Echo and myocardial contrast echocardiography perfusion imaging
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses.
Study: NCT01694134
Drug: Hydrocortancyl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an intradiscal injection of hydrocortancyl.
Study: NCT00634504
Drug: glucarpidase, high-dose methotrexate, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous dose
Study: NCT00634504
Drug: high-dose methotrexate, leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care, leucovorin every 6 hours
Study: NCT00676143
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Study: NCT01513499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Placebo single-dose administration
Study: NCT00324610
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01374841
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
Study: NCT00113503
Drug: Azathioprine weight-based dose
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00113503
Drug: Azathioprine individualised dose
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04545385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo